Flow Cytometry Findings for T-LGL Leukemia
For T-LGL leukemia diagnosis, look for an expanded population of CD3+/CD8+/CD57+ T cells (typically >0.4-0.5 × 10⁹/L or >30% of lymphocytes) with aberrant loss of pan-T-cell markers (commonly CD5 or CD7), and when flow cytometry is negative, the COMPASS molecular assay detects clonal T-cell receptor gene rearrangements and STAT3/STAT5B mutations that flow cytometry cannot identify.
Key Flow Cytometry Markers to Evaluate
The immunophenotypic profile you should specifically look for includes:
- CD3+/CD8+/CD57+: This is the classic triad for T-LGL leukemia 1, 2
- Aberrant antigen expression: Loss of CD5 or CD7 is common and helps distinguish clonal from reactive populations 3, 1
- CD4-/CD8+ subtype: Most common presentation (though CD4-/CD8- variants exist, particularly in γδ T-LGL) 4
- Absolute LGL count: Persistent elevation >0.5 × 10⁹/L for at least 6 months supports diagnosis 2, 5
- Percentage threshold: LGL cells typically comprise >30% of peripheral blood lymphocytes 3
Important Caveats
Flow cytometry can miss T-LGL leukemia in several scenarios. The "splenic variant" presents with splenomegaly and bone marrow involvement but minimal to no detectable tumor cells in peripheral blood, making flow cytometry falsely negative 4. Additionally, some patients have low-level clonal expansions below the detection threshold of standard flow cytometry.
What COMPASS Adds Beyond Flow Cytometry
When flow cytometry is negative or equivocal, COMPASS molecular testing provides three critical additional layers:
1. T-Cell Receptor Clonality Detection
COMPASS identifies clonal TCR gene rearrangements (TCR-γ, TCR-β, TCR-δ) that definitively prove clonality even when immunophenotyping is unrevealing 6, 4. This is particularly valuable because:
- Flow cytometry only suggests clonality through aberrant marker expression
- Molecular clonality confirms the diagnosis when morphology and immunophenotype are borderline
- It can detect clones present at lower frequencies than flow cytometry's sensitivity threshold
2. STAT3 and STAT5B Mutation Analysis
COMPASS detects activating mutations in STAT3 (present in ~80% of T-LGL cases) and STAT5B that flow cytometry cannot identify 2, 4, 7. These mutations:
- Confirm the diagnosis when other features are ambiguous
- Correlate with clinical severity, particularly neutropenia and infection risk in STAT3-mutated cases 7
- Guide prognosis and potentially inform treatment decisions
3. Quantitative Clonal Burden Assessment
COMPASS provides variant allele frequencies that quantify the clonal burden across different tissue compartments (blood, bone marrow, spleen), which is impossible with flow cytometry alone 4. This helps:
- Identify cases with predominant splenic or bone marrow involvement
- Monitor treatment response more sensitively
- Distinguish true clonal expansion from reactive processes
Clinical Algorithm for Suspected T-LGL
When you suspect T-LGL leukemia:
- Order flow cytometry first looking specifically for CD3+/CD8+/CD57+ cells with aberrant CD5 or CD7 loss
- If flow cytometry shows typical findings: Diagnosis is established; proceed with clinical correlation and treatment decisions
- If flow cytometry is negative but clinical suspicion remains high (persistent unexplained neutropenia, splenomegaly, rheumatoid arthritis association): Order COMPASS or equivalent molecular testing for TCR clonality and STAT mutations 2, 5
- If both are negative: Consider bone marrow biopsy with immunohistochemistry, particularly if splenomegaly is present (to exclude splenic variant) 4
The combination approach is essential because molecular testing detects 15-20% of cases that flow cytometry misses, particularly those with low peripheral blood involvement or unusual immunophenotypes 6, 2.